Therapeutic Vaccines

Collaboration targets development of RC-529 adjuvant

Published in Vaccine Weekly, September 10th, 2003

Corixa Corp. (CRXA) and Apovia AG announced a research, development, and commercialization agreement for Corixa's synthetic adjuvant, RC-529.

The multiyear agreement grants Apovia commercial rights to RC-529 for use in an undisclosed therapeutic vaccine. Both companies will equally share research, development and commercialization costs, as well as any potential product revenue.

"RC-529 adjuvant is a synthetic adjuvant that has been shown to stimulate immune responses to multiple vaccine antigen formulations both in animal models and in man," said Steven Gillis, PhD, chairman and chief executive officer at Corixa. "We look forward to continuing the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-09-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry